Big Pharma Patent Cliffs Driving Increased Activity in Oncology M&A

Sunday, 10 March 2024, 17:08

Cantor Fitzgerald predicts a robust year for oncology mergers and acquisitions as large pharmaceutical companies seek to bolster their pipelines in anticipation of upcoming patent expirations for key products. The looming patent cliffs are pushing major drugmakers to pursue strategic acquisitions within the oncology sector. This trend is likely to result in a flurry of deal-making activities that could reshape the landscape of the pharmaceutical industry, especially in the oncology space.

https://store.livarava.com/43e158d4-df01-11ee-965f-5254a2021b2b.jpe — Big Pharma Patent Cliffs Driving Increased Activity in Oncology M&A

Overview

Cantor Fitzgerald anticipates a surge in oncology mergers and acquisitions driven by patent cliffs affecting major pharmaceutical companies.

Key Points

Strategic Moves: Major drugmakers are exploring acquisitions to counter patent expirations of top-selling drugs.
Oncology Focus: The heightened activity is particularly prominent in the oncology sector.
Impact on Industry: The wave of M&A deals is poised to reshape the pharmaceutical landscape.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Overview

Key Points

Related posts